Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 6263

Sort by

Sort Order Select

Journal Articles

To start and stop or just keep going?

John G. Gribben

Blood (2021) 138 (10): 819–820.

https://doi.org/10.1182/blood.2021012675

Published: 2021

Journal Articles

Notch signaling promotes disease initiation and progression in murine chronic lymphocytic leukemia

Delphine Tardivon, Mateusz Antoszewski, Nadine Zangger, Marianne Nkosi, Jessica Sordet-Dessimoz, Rudi Hendriks, Ute Koch, Freddy Radtke

Blood (2021) 137 (22): 3079–3092.

https://doi.org/10.1182/blood.2020006701

Published: 2021

Includes: Supplemental data

Journal Articles

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

Blood (2021) 137 (22): 3093–3104.

https://doi.org/10.1182/blood.2020007626

Published: 2021

Includes: Supplemental data

Journal Articles

Progression signature underlies clonal evolution and dissemination of multiple myeloma

Yu Jia Shen, Yuji Mishima, Jiantao Shi, Romanos Sklavenitis-Pistofidis, Robert A. Redd, Michele Moschetta, Salomon Manier, Aldo M. Roccaro, Antonio Sacco, Yu-Tzu Tai, Francois Mercier, Yawara Kawano, Nang Kham Su, Brianna Berrios, John G. Doench, David E. Root, Franziska Michor, David T. Scadden, Irene M. Ghobrial

Blood (2021) 137 (17): 2360–2372.

https://doi.org/10.1182/blood.2020005885

Published: 2021

Includes: Supplemental data

Journal Articles

Preleukemic and leukemic evolution at the stem cell level

Jacob Stauber, John M. Greally, Ulrich Steidl

Blood (2021) 137 (8): 1013–1018.

https://doi.org/10.1182/blood.2019004397

Published: 2021

Journal Articles

Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria

Lova Sun, Daria V. Babushok

Blood (2020) 136 (1): 36–49.

https://doi.org/10.1182/blood.2019000940

Published: 2020

Journal Articles

Genetics of progression from MDS to secondary leukemia

Andrew J. Menssen, Matthew J. Walter

Blood (2020) 136 (1): 50–60.

https://doi.org/10.1182/blood.2019000942

Published: 2020

Journal Articles

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia

Blood (2020) 135 (26): 2337–2353.

https://doi.org/10.1182/blood.2020004834

Published: 2020

Includes: Supplemental data

Journal Articles

CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression

Blood (2020) 135 (15): 1244–1254.

https://doi.org/10.1182/blood.2019003179

Published: 2020

Includes: Supplemental data

Journal Articles

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL

Blood (2020) 135 (6): 411–428.

https://doi.org/10.1182/blood.2019001262

Published: 2020

Includes: Supplemental data

Journal Articles

B-cell–specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion

Daniela Asslaber, Yuan Qi, Nicole Maeding, Markus Steiner, Ursula Denk, Jan Philip Höpner, Tanja Nicole Hartmann, Nadja Zaborsky, Richard Greil, Alexander Egle

Blood (2019) 134 (20): 1717–1729.

https://doi.org/10.1182/blood.2019000973

Published: 2019

Includes: Supplemental data

Journal Articles

Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis

Blood (2019) 134 (Supplement_1): 3982.

https://doi.org/10.1182/blood-2019-124783

Published: 2019

Journal Articles

Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies

Blood (2019) 134 (Supplement_1): 3805.

https://doi.org/10.1182/blood-2019-129262

Published: 2019

Journal Articles

Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity

Hong Mu-Mosley, MD PhD, Lauren B Ostermann, Muharrem Muftuoglu, MD, Wendy Schober, Nalini B Patel, Abishek Vaidya, MS, Challice L. Bonifant, MD PhD, Stephen Gottschalk, MD, Mireya Paulina Velasquez, MD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3917.

https://doi.org/10.1182/blood-2019-125928

Published: 2019

Journal Articles

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

Blood (2019) 134 (Supplement_1): 3919.

https://doi.org/10.1182/blood-2019-130635

Published: 2019

Journal Articles

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Scott R. Solomon, MD, Aziz Nazha, MD, Stephen A. Strickland, MD, Roland B. Walter, MD PhD MS, Ilaria Valimberti, Alessia Tagliavini, Paolo Mazzei, Caterina Fiesoli, Simona Scartoni, Daniela Bellarosa, Monica Binaschi, PhD, Pawel Chrom, MD PhD, Simone Baldini, MD, Krzysztof Brzózka, PhD, Angela Capriati, Andrea Pellacani, PhD MD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 3920.

https://doi.org/10.1182/blood-2019-125878

Published: 2019

Journal Articles

Preclinical Evaluation of ALLO-819, an Allogeneic CAR T Cell Therapy Targeting FLT3 for the Treatment of Acute Myeloid Leukemia

Cesar Sommer, PhD, Hsin-Yuan Cheng, PhD, Yik Andy Yeung, PhD, Duy Nguyen, Janette Sutton, Zea Melton, Julien Valton, PhD, Kris Poulsen, Ivana Djuretic, PhD, Thomas Van Blarcom, PhD, Javier Chaparro-Riggers, PhD, Barbra Sasu, PhD

Blood (2019) 134 (Supplement_1): 3921.

https://doi.org/10.1182/blood-2019-129025

Published: 2019

Journal Articles

DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment

Judith Eckl, PhD, Silke Raffegerst, PhD, Frauke Schnorfeil, PhD, Petra Prinz-Schulz, PhD, Christiane Fingerhut, Yngvar Floisand, MD PhD, Dag Josefsen, Iris Bigalke, MD, Kai Pinkernell, MDMBA, Gunnar Kvalheim, MD PhD, Dolores Schendel, Prof., Anna Tafuri, MD

Blood (2019) 134 (Supplement_1): 3923.

https://doi.org/10.1182/blood-2019-129749

Published: 2019

Journal Articles

Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML

Amanda R. Leonti, MS, Laura Pardo, Todd A. Alonzo, PhD, Robert B. Gerbing, Lisa Eidenschink Brodersen, PhD, Rhonda E. Ries, MA, Jenny L. Smith, MSc, MD, Quy Le, PhD, Richard Aplenc, MD PhD, E. Anders Kolb, MD, John L. Magnani, PhD, William E. Fogler, PhD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 3772.

https://doi.org/10.1182/blood-2019-124525

Published: 2019

Journal Articles

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Elias Jabbour, MD, Marina Y Konopleva, MD PhD, Farhad Ravandi, MD, Courtney D. DiNardo, MDMSc, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD

Blood (2019) 134 (Supplement_1): 3926.

https://doi.org/10.1182/blood-2019-131930

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

To start and stop or just keep going?

Notch signaling promotes disease initiation and progression in murine chronic lymphocytic leukemia

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

Progression signature underlies clonal evolution and dissemination of multiple myeloma

Preleukemic and leukemic evolution at the stem cell level

Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria

Genetics of progression from MDS to secondary leukemia

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia

CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL

B-cell–specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion

Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis

Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies

Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Preclinical Evaluation of ALLO-819, an Allogeneic CAR T Cell Therapy Targeting FLT3 for the Treatment of Acute Myeloid Leukemia

DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment

Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only